AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9315788
Drug: As-needed inhaled
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As-needed inhaled beta-agonist therapy
Trial: 8157042
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion glucagon
Trial: 2872870
Drug: Family treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family treatment
Trial: 2872870
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of family treatment and social skills training
Trial: 2872870
Drug: Drug-treated condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-treated condition (Control)
Trial: 30513795
Drug: High-dose B-group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose B-group vitamin supplementation
Trial: 24717247
Drug: Taper (desvenlafaxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper (desvenlafaxine 25 mg/d)
Trial: 24717247
Drug: Abrupt discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrupt discontinuation (placebo)
Trial: 24717247
Drug: No discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No discontinuation (desvenlafaxine 50 mg/d)
Trial: 20445353
Drug: Combined immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined immunotherapy treatment with rIL-2 and IFN-alpha
Trial: 20445353
Drug: NHL patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NHL patients treated with immunotherapy
Trial: 15629825
Drug: 2% gel
RxNorm normalized name: SULFUR 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% gel twice daily (gel/gel)
Trial: 15629825
Drug: 2% gel
RxNorm normalized name: SULFUR 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% gel daily (evening, placebo/gel)
Trial: 15629825
Drug: Vehicle twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle twice daily (placebo/placebo)
Trial: 11973494
Drug: POM 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POM 1.0 mg/kg
Trial: 11973494
Drug: INM 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INM 0.4 mg/kg
Trial: 11973494
Drug: POD 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POD 0.5 mg/kg
Trial: 7478701
Drug: Ketamine (0-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0-40 mg, i.m., 8 times per day)
Trial: 24793536
Drug: FF/VI (fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/VI (fluticasone furoate/vilanterol), 100/25 µg
Trial: 24793536
Drug: FF (fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF (fluticasone furoate), 100 µg
Trial: 19953771
Drug: Whitestrips (strips,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whitestrips (strips, twice a day, 30 minutes each for two weeks)
Trial: 3281764
Drug: Indomethacin (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.35 mg.kg‐1 bolus followed by 0.07 mg.kg‐1.hr‐1 infusion for 24 hr)
Trial: 25076278
Drug: Ylang ylang
RxNorm normalized name: ylang-ylang oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ylang ylang essential oil by inhalation
Trial: 23332981
Drug: Reduced injection
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced injection frequency
Trial: 23332981
Drug: Concurrent decreased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent decreased drug injection and increased alcohol consumption
Trial: 19450093
Drug: High-dosage medical
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage medical exercise therapy (HD)
Trial: 19450093
Drug: Low-dosage medical
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage medical exercise therapy (LD)
Trial: 16686385
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of 2% lidocaine and adrenaline 1:200,000 (group I)
Trial: 16686385
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of 1% lidocaine and adrenaline 1:400,000 (group II)
Trial: 16686385
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of 1% lidocaine and adrenaline 1:200,000 (group III)
Trial: 16686385
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of 1% lidocaine (group IV)
Trial: 12839378
Drug: Triple therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy: lansoprazole 30 mg twice daily, amoxycillin 500 mg four times daily, clarithromycin 500 mg twice a day for 10 days
Trial: 12839378
Drug: Quadruple therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy: tri-potassium dicitrato bismuthate 120 mg four times daily, metronidazole 400 mg thrice daily, tetracycline 500 mg four times daily for 10 days
Trial: 10791133
Drug: Albuterol plus
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol plus prednisolone
Trial: 10791133
Drug: Albuterol plus
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol plus placebo
Trial: 29668448
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of tranexamic acid per kg (group A)
Trial: 24726066
Drug: Home-based occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based occupational therapy for 10 weeks according to national practice guidelines
Trial: 24726066
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care with no occupational therapy
Trial: 23610854
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% with sufentanil 0.5 microg/ml (group 1)
Trial: 23610854
Drug: Ropivacaine 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.125% with sufentanil 0.5 microg/ml (group 2)
Trial: 23610854
Drug: Levobupivacaine 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.125% with sufentanil 0.5 microg/ml (group 3)
Trial: 20491746
Drug: PN 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PN 400 containing 30 mg esomeprazole
Trial: 20491746
Drug: PN 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PN 400 containing 20 mg esomeprazole
Trial: 20491746
Drug: PN 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PN 400 containing 10 mg esomeprazole
Trial: 20491746
Drug: Naproxen plus
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen plus esomeprazole 20 mg
Trial: 17564755
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg retarded release levodopa/carbidopa
Trial: 17564755
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg levodopa/carbidopa/entacapone
Trial: 10607255
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil 125 mg (n = 15)
Trial: 10607255
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil 125 mg
Trial: 7829789
Drug: Cilazapril 1
RxNorm normalized name: cilazapril 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 1 mg twice daily
Trial: 7829789
Drug: Cilazapril 5
RxNorm normalized name: cilazapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 5 mg twice daily
Trial: 7829789
Drug: Cilazapril 10
RxNorm normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 10 mg twice daily
Trial: 79764
Drug: Polyvalent pseudomonas
RxNorm normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyvalent pseudomonas vaccine
Trial: 30538070
Drug: IN Ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN Ketamine (1 ml = 50 mg)
Trial: 30538070
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline, 1 ml)
Trial: 22926087
Drug: Fatigue assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fatigue assessment using the subscale of the Checklist Individual Strength, assessed monthly between T2 and T3.
Trial: 22926087
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for postcancer fatigue, aimed at the fatigue-perpetuating factors, could be offered from two months after successful cancer treatment.
Trial: 21977863
Drug: Fluoxetine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (n = 40)
Trial: 19700194
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg at baseline and months 1, 3, and 5)
Trial: 19700194
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ranibizumab (0.5 mg) and focal/grid laser (at baseline and month 3)
Trial: 19700194
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ranibizumab and focal/grid laser
Trial: 9404431
Drug: Monotherapy in
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy in the 80 mmHg target group
Trial: 8453217
Drug: Elective red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective red cell transfusion to maintain capillary haematocrit greater than 0.35 l/1 (group 1)
Trial: 3705896
Drug: Naloxone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (4 mg) mixed with 10 ml of orange juice
Trial: 3705896
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline mixed with 10 ml of orange juice
Trial: 19194534
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy alone (highest tertile risk)
Trial: 10430114
Drug: Accelerated titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated titration regimen of sotalol (80 mg every 6 hours for four doses, then 160 mg every 12 hours for nine doses)
Trial: 10430114
Drug: Standard titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard titration regimen of sotalol (80 mg every 6 hours for eight doses, then 160 mg every 12 hours for nine doses)
Trial: 7756495
Drug: Cefazolin (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1-g intravenous dose)
Trial: 7756495
Drug: Cefotetan (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (1-g intravenous dose)
Trial: 2405040
Drug: Furosemide (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (approximately 28 mg) administered by inhalation
Trial: 6947990
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment (instruction and practice in oral hygiene techniques and meticulous prophylaxis) repeated every 2-3 months
Trial: 27684425
Drug: Oral colostrum
RxNorm normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral colostrum priming (OCP)
Trial: 27684425
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral colostrum priming (Control)
Trial: 7837153
Drug: Antibody to
RxNorm normalized name: Antibody to HPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody to purified 38-kDa protein of M. tuberculosis
Trial: 7837153
Drug: Antibody to
RxNorm normalized name: Antibody to HPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody to 65-kDa HSP of M. leprae
Trial: 25049140
Drug: Behavioural activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural activation treatment (up to 12 sessions)
Trial: 22652535
Drug: Extended daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended daily diafiltration (EDDF)
Trial: 20524719
Drug: rosuvastatin/fenofibric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin/fenofibric acid 20 mg/135 mg
Trial: 20524719
Drug: rosuvastatin/fenofibric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin/fenofibric acid 10 mg/135 mg
Trial: 20524719
Drug: rosuvastatin/fenofibric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin/fenofibric acid 5 mg/135 mg
Trial: 12209085
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance medications
Trial: 12209085
Drug: Mean daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean daily symptom code and use of albuterol for asthma symptoms
Trial: 12209085
Drug: Mean daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean daily symptom code and daily use of albuterol
Trial: 7565455
Drug: HOSS Ca
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOSS Ca (900 mg Ca/day)
Trial: 7565455
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (900 mg Ca/day)
Trial: 6156321
Drug: Prostaglandin A1
RxNorm normalized name: Prostaglandin A1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin A1 (PGA1) infusion at 1/microgram/kg/min during water loading
Trial: 6156321
Drug: Prostaglandin A1
RxNorm normalized name: Prostaglandin A1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin A1 (PGA1) infusion at 1/microgram/kg/min during water deprivation
Trial: 6156321
Drug: Prostaglandin A1
RxNorm normalized name: Prostaglandin A1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin A1 (PGA1) infusion with hypertonic mannitol during water deprivation
Trial: 30277455
Drug: Supplemental Cr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental Cr (0.05 mg Cr as Cr-methionine/kg of BW0.75)
Trial: 17504894
Drug: Pramlintide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide (up to 240 microg, self-administered via sc injection three times a day for 16 weeks)
Trial: 9842252
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 2% eye drops, one drop each eye, four times daily for 8 weeks
Trial: 2775153
Drug: Individual cognitive‐behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive‐behaviour therapy (ICBT)
Trial: 2775153
Drug: Group cognitive‐behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive‐behaviour therapy (GCBT)
Trial: 2775153
Drug: Individual cognitive‐behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive‐behaviour therapy (ICBT) vs Group cognitive‐behaviour therapy (GCBT)
Trial: 799975
Drug: Diftalone 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diftalone 500 mg per day
Trial: 24838782
Drug: Congruence Couple
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Congruence Couple Therapy (CCT) for 12 weeks
Trial: 23062489
Drug: Sitagliptin (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (50mg daily for 3 months)
Trial: 21320954
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment (ET)
Trial: 18664712
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg of methylphenidate
Trial: 10757456
Drug: cold solution
RxNorm normalized name: All-Nite Cold Solution
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cold solution (2-3 degrees C)
Trial: 10757456
Drug: hot solution
RxNorm normalized name: Goody's Headache Relief Shot Solution (Berry)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hot solution (55-58 degrees C)
Trial: 10757456
Drug: room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: room temperature solution (20-21 degrees C)
Trial: 10757456
Drug: lactose solution
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose solution (50 g)
Trial: 9351617
Drug: Colchicine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.6 mg twice a day)
Trial: 1609547
Drug: CVD 908
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 908 Salmonella typhi vaccine strain (5 x 10(7) organisms with sodium bicarbonate)
Trial: 1609547
Drug: CVD 908
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 908 Salmonella typhi vaccine strain (5 x 10(4) to 5 x 10(7) organisms with sodium bicarbonate)
Trial: 26911400
Drug: Triamcinolone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone (10 mg/ml)
Trial: 25002723
Drug: Cisplatin 30
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 30 mg/m(2) once per week with 60 Gy radiation and cetuximab once per week
Trial: 25002723
Drug: Docetaxel 15
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 15 mg/m(2) once per week with 60 Gy radiation and cetuximab once per week
Trial: 20955444
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg b.d.
Trial: 20955444
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg od before breakfast
Trial: 20955444
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg od before breakfast
Trial: 20955444
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg od before dinner or at bedtime
Trial: 18572351
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of 10% dextran-40
Trial: 16138948
Drug: Device therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Device therapy
Trial: 12436372
Drug: Glucocorticoids and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoids and non-steroidal antirheumatic drugs (NSAD)
Trial: 12436372
Drug: TNF-alpha-inhibiting drugs
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF-alpha-inhibiting drugs (etanercept, infliximab)
Trial: 11147027
Drug: 750 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 micrograms Fluticasone propionate (FP) twice daily for 3 months
Trial: 9176748
Drug: Intrapleurally instilled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleurally instilled mitoxantrone (30 mg)
Trial: 10621528
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir as prophylaxis against recurrent stromal keratitis
Trial: 9766780
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral treatment of residual symptoms
Trial: 21169002
Drug: Montelukast (CysLT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (CysLT receptor 1 antagonist)
Trial: 19906343
Drug: ORAL
RxNorm normalized name: Doral
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ORAL
Trial: 11948850
Drug: Nevirapina (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapina (test formulation)
Trial: 11948850
Drug: Viramune (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viramune (reference formulation)
Trial: 10407237
Drug: Continual low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continual low dose corticosteroid treatment
Trial: 511419
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 0.2 mg/kg body weight pirenzepine